Phase I study of Vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks
- 83 Downloads
Vinflunine is a novel vinca alkaloid developed through the selective modification of vinorelbine using super-acidic chemistry. In preclinical testing, vinflunine demonstrated significantly enhanced anti-tumour activity in human tumour xenograft models when compared to its parent compound. A phase I study was conducted to evaluate the safety and toxicity of vinflunine administered as a 10 minute intravenous infusion on days 1 and 8 every three weeks. Sixteen patients with advanced solid tumours were treated. Two of four patients experienced dose limiting toxicities (DLT) at 190 mg/m2 and this was established as the maximum tolerated dose (MTD). At the MTD, the DLT of vinflunine consisted of constipation and neutropenia. Fatigue was notable but not dose limiting. No objective responses were observed. A dose of 170 mg/m2 given on a day 1 and 8 schedule every three weeks would be suitable for future studies.
Key Wordsvinflunine phase I safety and toxicity
Unable to display preview. Download preview PDF.
- 1.Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, et al.: Randomized study of Vinorelbine and cisplatin versus vindesine and cisplatin versus Vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12(2): 360–7, 1994PubMedGoogle Scholar
- 3.Fahy JDA, Ribet JP, Jacquesy JC, Berrier C, Jouannetaud MP, F. Z. Vinca alkaloids in superacidic media: a method for creating a new family of antitumor derivatives. J Am Chem Soc 119(36): 8576–8577, 1997Google Scholar
- 9.Etiévant CKA, Chansard N, Cabrol N, Astruc J, Chazottes E, BT H: Characterization of apoptosis induced by vinflunine, a novel fluorinated vinca alkaloid, in sensitive and vinflunine resistant P388 tumor cells: concomitant cell cycle analysis. Proc Am Assoc Cancer Res 39: 166, 1998Google Scholar
- 14.Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2.0. DCTD, NCI, NIH, DHHS. March 1998Google Scholar
- 16.World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment [WHO Offest Publication No. 48]. Geneva S, World Health Organization, 1979Google Scholar
- 19.US Department of Health and Human Services FaDACC. Guidance for Industry — Bioanalytical method validation. May 2001Google Scholar